
https://www.science.org/content/blog-post/liable-generics-you-are-now
# Liable For Generics? You Are Now! (Nov 2008)

## 1. SUMMARY

The article discusses a California appellate court ruling in *Conte v. Wyeth*, a case involving metoclopramide, the generic version of Wyeth's Reglan (approved before 1982). The lawsuit was filed against Wyeth (the original "pioneer" manufacturer) over side effects from a generic version the plaintiff took, even though Wyeth had not made or sold that generic. The piece explains this ruling departs from traditional product-liability doctrine, which typically holds only the manufacturer of the specific product that caused harm liable. The author argues that imposing perpetual liability on pioneer manufacturers for generics they no longer manufacture, label, or profit from would likely increase the costs of new drugs, since pioneer firms must recoup those liabilities from their current, patented products. The article also notes that the case was likely headed to the California Supreme Court and possibly the U.S. Supreme Court.

## 2. HISTORY

The *Conte v. Wyeth* legal theory did not ultimately become the dominant national rule in the United States. While it received attention in California and some other jurisdictions, the approach was largely eclipsed by arguments centered on federal preemption of state failure-to-warn claims. Subsequently, in **PLIVA, Inc. v. Mensing** (2011), the U.S. Supreme Court held that federal law preempts state failure-to-warn claims against generic manufacturers when the generic's label must match the FDA-approved brand-name label, creating a liability disparity between brand and generic makers. Soon after, in **Mutual Pharmaceutical Co. v. Bartlett** (2013), the Supreme Court ruled that state design-defect claims against generic drugs were also preempted. Following those decisions, FDA efforts around "generic labeling flexibility" (proposed rules, public meetings) did not yield a final rule enabling independent generic label updates, leaving preemption largely intact for generics.

Wyeth itself was acquired by Pfizer in 2009, and metoclopramide remains an older, widely used generic medication. Overall, the articleâ€™s concern about a broad expansion of pioneer-manufacturer liability for generics did not materialize nationally, with the legal landscape shifting instead toward preemption that generally shields generic manufacturers from certain failure-to-warn claims, rather than exposing brand manufacturers to liability for generic products.

## 3. PREDICTIONS

- **That *Conte* would hold up and be with us "for a good long while."**
  - Not accurate. *Conte* drew attention but did not become the prevailing national standard. The U.S. Supreme Court's decisions in *Mensing* and *Bartlett* established federal preemption principles that largely displaced *Conte*-style theories in most U.S. jurisdictions.

- **Imposing liability in perpetuity on pioneer manufacturers for products they no longer sell would cause the cost of new drugs to rise.**
  - Not validated. Because the *Conte* rationale did not become the general rule nationwide, there is no systematic evidence that it drove broad price increases for new drugs. Drug pricing dynamics have been dominated by patent and market factors, not widespread liability for generic versions.

- **That the favorable ruling for plaintiffs represented a new legal norm.**
  - Not sustained. After initial commentary support for the plaintiff in some quarters, the national legal trajectory turned toward preemption, generally shielding generic manufacturers and limiting the reach of *Conte*-style claims across most of the U.S.

## 4. INTEREST 
Rating: **6/10**

The article captures an important legal moment in pharmaceutical liability and highlights a plausible risk to innovation incentives, but the specific legal theory it examined did not ultimately become the dominant framework in the U.S. It remains a useful illustration of how courts test novel liability theories and how those theories can be superseded or narrowed by subsequent precedent (here, via federal preemption).


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20081117-liable-generics-you-are-now.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_